Clinical Characterization and Outcomes of Dupilumab for Pemphigoid Gestationis: A Case Series of Five Patients and Literature Review
Authors:
- Joost M. MeijerJMJoost M. Meijer
- Elise J. LeemanELElise J. Leeman
- Lisette M. PrensLPLisette M. Prens
- Klasiena BouwmanKBKlasiena Bouwman
- Jelmer R. PrinsJPJelmer R. Prins
- Sanne J. GordijnSGSanne J. Gordijn
- Mirthe H. SchootsMSMirthe H. Schoots
- Maria C. BollingMBMaria C. Bolling
- Gilles F. H. DiercksGDGilles F. H. Diercks
- Jeroen BremerJBJeroen Bremer
- Barbara HorváthBHBarbara Horváth
Open Access
- 28 July 2026
- journal article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Abstract
Treatment of pemphigoid gestationis (PG) mainly consists of systemic and potent topical corticosteroids. This retrospective case series describes patients with severe PG treated with dupilumab, including serological follow-up, and reviews all published cases. PG was confirmed by direct immunofluorescence (linear C3 and/or IgG deposition along the basement membrane zone) and serology (IgG epidermal staining on salt-split skin or anti-BP180 NC16A IgG ELISA). Pruritus, quality of life and anti-BP180 NC16A IgG and anti-BP180 NC16A IgE were monitored longitudinally. In 5 pregnant women, dupilumab was initiated with a 600 mg loading dose followed by 300 mg biweekly. Baseline pruritus was severe (NRS 8–10), with high DLQI scores (18–30). Blistering ceased within 1 week in 2 patients and within 4 weeks in 1. Two patients required weekly dosing for disease control. Systemic corticosteroids were discontinued in 3 patients and tapered to ≤10 mg/day in 2 before delivery. In one case, anti-BP180 IgG paralleled clinical improvement. Anti-BP180 IgE remained negative. All patients delivered healthy infants. In 10 reported cases, pruritus improved rapidly and systemic corticosteroids were tapered. These findings suggest dupilumab may be a promising corticosteroid-sparing option for PG, with rapid clinical response and a favourable safety profile, despite off-label use in pregnancy.Keywords
This publication has 27 references indexed in Scilit:
- Successful Use of Dupilumab in the Management of Recalcitrant Pemphigoid GestationisAustralasian Journal of Dermatology, 2025
- Dupilumab as a novel steroid-sparing treatment for pemphigoid gestationis: A new case report and review of literatureJAAD Case Reports, 2025
- Evaluation Of Maternal And Fetal Findings In Patients With Pemphigoid GestationisInternational Journal of Gynecology & Obstetrics, 2024
- Pemphigoid gestationis is associated with an increased risk for adverse pregnancy outcomes: A large-scale propensity-matched retrospective cohort studyJournal of the American Academy of Dermatology, 2024
- Safety of dermatologic medications in pregnancy and lactation: An update—Part II: LactationJournal of the American Academy of Dermatology, 2024
- Pemphigoid gestationis treated with dupilumabJAAD Case Reports, 2023
- Pemphigoid Gestationis and adverse pregnancy outcomes: A literature reviewJournal of Gynecology Obstetrics and Human Reproduction, 2022
- Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of PemphigoidJAMA Dermatology, 2019
- Pemphigoid gestationis autoantigen, transmembrane collagen XVII, promotes the migration of cytotrophoblastic cells of placenta and is a structural component of fetal membranesMatrix Biology, 2008
- Abnormal expression of HLA-DR antigen in the placenta of a patient with pemphigoid gestationisJournal of Reproductive Immunology, 1984